Close Menu

NEW YORK – JP Morgan on Thursday upgraded Qiagen's stock to Overweight from Underweight following a buy-side survey, two product surveys, and a valuation analysis.

JP Morgan issued the note a day after Bloomberg reported that Qiagen could be an acquisition target for Thermo Fisher Scientific, sending shares of Qiagen soaring in trading on the New York Stock Exchange.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by

This webinar will provide a first-hand look at how a clinical lab evolved its tumor profiling workflow from a targeted panel approach toward comprehensive genomic profiling.  

Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.